inhibikase.com/news/press-r...
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
Inhibikase announces that they will empl... - Cure Parkinson's
Inhibikase announces that they will employ the new alpha-synuclein seed amplification assay biomarker in its ongoing Phase IIa trial
2 Replies
•
Great news!
I just heard about this today. Sounds promising !
Not what you're looking for?
You may also like...
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
As of 24 Feb 2024:
- Recruitment continues and is reaching the halfway point (59 of 120);
- 25...
Phase 3 Positive Topline Results for Tavapadon
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial...
Potential Parkinson’s Treatment, CDNF, Shows Safety and Tolerability at One Year
A potential Parkinson’s treatment called cerebral dopamine neurotrophic factor (CDNF) continues to...
As Parkinson’s patients wait, Fox Foundation and scientist feud over Nilotinib drug trial
https://www.statnews.com/2016/08/30/parkinsons-study-fox-foundation-feud/
Nilotinib, a blood cancer...
Related Posts
Starting phase 2 trial : Terazosin for Parkinson's Disease (TZ-PD)
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.
BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107,ERK inhibitor that selectively inhibits neuroinflammation- Bayer reports positive early data for Parkinson’s cell therapy
